VivoSim Labs, INC. (VIVS)
VivoSim Labs (NASDAQ: VIVS), formerly Organovo, has pivoted from clinical‐stage drug development to offering premium
3D human tissue testing services in liver and intestinal toxicology. FDA endorsement of non-animal NAM methods is
a major catalyst. The Company sold its FXR program to Eli Lilly fo...